# A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

> **NCT04970901** · PHASE1 · RECRUITING · sponsor: **ADC Therapeutics S.A.** · enrollment: 200 (estimated)

## Conditions studied

- B-Cell Non-Hodgkin Lymphoma
- Relapsed B-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Loncastuximab Tesirine
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Glofitamab
- **DRUG:** Mosunetuzumab
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04970901
- **Lead sponsor:** ADC Therapeutics S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-17
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-10-29
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04970901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04970901, "A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04970901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*